NCI Objects To Fisher As Scientific Director Of NSABP, Threatens To Cut Off Funding
In Brief: Senate Cancer Coalition Hearing On Tamoxifin Planned for May 11; Bresnick Leads AACR
Fisher and Redmond Subject Of Misconduct Investigation; ORI
Herberman Outlines NSABP restructuring In Plan To NCI
DCT Advisors Approve Increased Spending On Trials Monitoring
Possible Breach of Patient Confidentially By Calif. Physician; NCI
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years
- NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Most Favored Nation drug pricing could put China on top
- Protecting the cure: Why the future of radiation oncology must be precision-guided









